Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
Protocol ID
MK-7902-013
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapsed/refractory
Sponsor
Merck Sharp & Dohme Corp.
Collaborators
Eisai Inc.
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 2
Age Eligibility
2 Years to 21 Years
International registry ID's
NCT04447755
| Study Title | An Open-Label Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children Adolescents and Young Adults with Relapsed or Refractory Solid Malignancies |
|---|---|
| Protocol ID | MK-7902-013 |
| Disease (Sub Disease) | Solid tumours |
| Diagnosis Stage | Relapsed/refractory |
| Sponsor | Merck Sharp & Dohme Corp. |
| Collaborators | Eisai Inc. |
| Links | https://clinicaltrials.gov/ct2/show/NCT04447755 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 30/07/2020 |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 2 Years to 21 Years |
| International registry ID's | NCT04447755 |